Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Enrolls First in ZUPREME-2 Trial of Petrelintide for Obesity And T2D
Details : ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : Inapplicable
April 24, 2025
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Completes Phase 2b Enrollment for Petrelintide in Obesity
Details : ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petrelintide,CT-388
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : F. Hoffmann-La Roche
Deal Size : $5,300.0 million
Deal Type : Collaboration
Roche & Zealand Partner to Develop Petrelintide for Obesity & Overweight Therapy
Details : The two companies will collaborate to co-develop and co-commercialise ZP8396 (petrelintide) in combination with CT-388 for the treatment of obesity.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : $1,650.0 million
March 12, 2025
Lead Product(s) : Petrelintide,CT-388
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : F. Hoffmann-La Roche
Deal Size : $5,300.0 million
Deal Type : Collaboration
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Pharma Enrolls First Participant in Phase 2b ZUPREME-1 Trial of Petrelintide
Details : ZP8396 (petrelintide) is an potent long-acting amylin analogue designed to improve solubility, minimize fibrillation, holdin a potential for the treatment of overweight.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand's Petrelintide Shows Positive Phase 1b Results
Details : ZP8396 (petrelintide) is an potent long-acting amylin analogue designed to improve solubility, minimize fibrillation, holdin a potential for the treatment of overweight.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : Inapplicable
June 20, 2024
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
Details : ZP8396 is an investigational, potent long-acting amylin analogue designed to improve solubility, minimize fibrillation and allow for co-formulation with other peptides, including GLP-1 analogues, it holds potential for the treatment of obesity.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZP8396 is an investigational, potent long-acting amylin analogue designed to improve solubility, minimize fibrillation and allow for co-formulation with other peptides, including GLP-1 analogues, it holds potential for the treatment of obesity.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : Inapplicable
March 07, 2023
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable